FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023561451> ?p ?o ?g. }

• W2023561451 endingPage "1241" @default.
• W2023561451 startingPage "1234" @default.
• W2023561451 abstract "Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti-angiogenic activity, this study was designed to investigate the potential role of Th in the treatment of patients with AML and MDS and the possible role of a non-ara-C-containing regimen.Adults with AML or high-risk MDS and cytogenetic abnormalities other than inv (16), t(8;21), -Y or -X were randomized to receive liposomal daunorubicin (DNX) and ara-C (DA) or DNX and topotecan (DT). Within each arm, patients were randomized to receive chemotherapy alone (DA or DT) or with thalidomide (DATh or DTTh). Vascular endothelial growth factor (VEGF) plasma levels and microvascular density was measured before and after therapy. Eighty-four patients (median age, 65 years; range, 27-84 years) were treated.None of 11 patients treated with DT or DTTh responded and these arms were closed. Seventeen of 37 patients treated with DA and 15 of 36 treated with DATh achieved an early complete remission. Median complete response duration was 38 and 34 weeks (P = 0.57) and median survival 35 and 28 weeks (P = 0.15), respectively. Patients with high pretreatment VEGF levels had an inferior survival. There was no significant difference in the changes in VEGF levels or microvascular density after treatment in patients who did versus those who did not receive thalidomide.The authors concluded that thalidomide in combination with chemotherapy does not result in clinical benefit in patients with AML or high-risk MDS." @default.
• W2023561451 created "2016-06-24" @default.
• W2023561451 creator A5006104041 @default.
• W2023561451 creator A5015140142 @default.
• W2023561451 creator A5027575595 @default.
• W2023561451 creator A5027800341 @default.
• W2023561451 creator A5028026524 @default.
• W2023561451 creator A5038307470 @default.
• W2023561451 creator A5046097970 @default.
• W2023561451 creator A5057920623 @default.
• W2023561451 creator A5061026876 @default.
• W2023561451 creator A5061285204 @default.
• W2023561451 creator A5079262854 @default.
• W2023561451 creator A5090435894 @default.
• W2023561451 date "2003-02-20" @default.
• W2023561451 modified "2023-10-18" @default.
• W2023561451 title "A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome" @default.
• W2023561451 cites W135651168 @default.
• W2023561451 cites W1567732942 @default.
• W2023561451 cites W1569016295 @default.
• W2023561451 cites W1756796371 @default.
• W2023561451 cites W182858095 @default.
• W2023561451 cites W1919339218 @default.
• W2023561451 cites W1965181694 @default.
• W2023561451 cites W1985147506 @default.
• W2023561451 cites W1985849470 @default.
• W2023561451 cites W2000366267 @default.
• W2023561451 cites W2006055464 @default.
• W2023561451 cites W2018803923 @default.
• W2023561451 cites W203706493 @default.
• W2023561451 cites W2044200030 @default.
• W2023561451 cites W2045079249 @default.
• W2023561451 cites W2076820945 @default.
• W2023561451 cites W2077753080 @default.
• W2023561451 cites W2077946724 @default.
• W2023561451 cites W2092766083 @default.
• W2023561451 cites W2100449898 @default.
• W2023561451 cites W2115587079 @default.
• W2023561451 cites W2117327010 @default.
• W2023561451 cites W2170446694 @default.
• W2023561451 cites W2190800131 @default.
• W2023561451 cites W2201158929 @default.
• W2023561451 cites W2316160054 @default.
• W2023561451 cites W4233640732 @default.
• W2023561451 cites W4240674955 @default.
• W2023561451 cites W4381937407 @default.
• W2023561451 doi "https://doi.org/10.1002/cncr.11180" @default.
• W2023561451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12599230" @default.
• W2023561451 hasPublicationYear "2003" @default.
• W2023561451 type Work @default.
• W2023561451 sameAs 2023561451 @default.
• W2023561451 citedByCount "43" @default.
• W2023561451 countsByYear W20235614512012 @default.
• W2023561451 countsByYear W20235614512013 @default.
• W2023561451 countsByYear W20235614512015 @default.
• W2023561451 countsByYear W20235614512016 @default.
• W2023561451 countsByYear W20235614512017 @default.
• W2023561451 countsByYear W20235614512018 @default.
• W2023561451 countsByYear W20235614512019 @default.
• W2023561451 countsByYear W20235614512020 @default.
• W2023561451 crossrefType "journal-article" @default.
• W2023561451 hasAuthorship W2023561451A5006104041 @default.
• W2023561451 hasAuthorship W2023561451A5015140142 @default.
• W2023561451 hasAuthorship W2023561451A5027575595 @default.
• W2023561451 hasAuthorship W2023561451A5027800341 @default.
• W2023561451 hasAuthorship W2023561451A5028026524 @default.
• W2023561451 hasAuthorship W2023561451A5038307470 @default.
• W2023561451 hasAuthorship W2023561451A5046097970 @default.
• W2023561451 hasAuthorship W2023561451A5057920623 @default.
• W2023561451 hasAuthorship W2023561451A5061026876 @default.
• W2023561451 hasAuthorship W2023561451A5061285204 @default.
• W2023561451 hasAuthorship W2023561451A5079262854 @default.
• W2023561451 hasAuthorship W2023561451A5090435894 @default.
• W2023561451 hasConcept C126322002 @default.
• W2023561451 hasConcept C141071460 @default.
• W2023561451 hasConcept C143998085 @default.
• W2023561451 hasConcept C168563851 @default.
• W2023561451 hasConcept C2776364478 @default.
• W2023561451 hasConcept C2776694085 @default.
• W2023561451 hasConcept C2778041864 @default.
• W2023561451 hasConcept C2778461978 @default.
• W2023561451 hasConcept C2779609412 @default.
• W2023561451 hasConcept C2780007613 @default.
• W2023561451 hasConcept C2780817109 @default.
• W2023561451 hasConcept C2781021840 @default.
• W2023561451 hasConcept C2781209748 @default.
• W2023561451 hasConcept C2781413609 @default.
• W2023561451 hasConcept C71924100 @default.
• W2023561451 hasConcept C90924648 @default.
• W2023561451 hasConceptScore W2023561451C126322002 @default.
• W2023561451 hasConceptScore W2023561451C141071460 @default.
• W2023561451 hasConceptScore W2023561451C143998085 @default.
• W2023561451 hasConceptScore W2023561451C168563851 @default.
• W2023561451 hasConceptScore W2023561451C2776364478 @default.
• W2023561451 hasConceptScore W2023561451C2776694085 @default.
• W2023561451 hasConceptScore W2023561451C2778041864 @default.
• W2023561451 hasConceptScore W2023561451C2778461978 @default.
• W2023561451 hasConceptScore W2023561451C2779609412 @default.

• next